Novo's Ozempic Notches Approval for Kidney Disease, Widening Use / Defense, Novo and Nestle: 2024 Highs and Lows in European Stocks / Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand? / Novo's Ozempic Reduced Opioid Overdose Risk, Research Shows / Lilly Gains in Obesity Race With Novo as Supplies Expand / Novo's Supply Crunch, Germany's Pain: EMEA Earnings Week Ahead / Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says / Wegovy maker Novo inks $16.5 billion acquisition of Catalent to boost supply / Why Obesity Drug Coverage Doesn't Matter (Yet) for Lilly and Novo / Lilly trades at a premium to Ozempic maker Novo as obesity drugs boom. Here's why, analyst says